Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF | T.LABS.W

MediPharm Labs Corp, along with its subsidiaries, produces purified, pharmaceutical-like cannabis extracts and related derivative products. The company generates revenue from Private label, White label, the Tolling process, and others. Some of its vape brands are Northern Lights, Blue Dream, 2:1 CBD:THC, Pink Kush and GG4. Its geographical segments are Canada and Australia.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Don't miss the conference call on Monday, more news

is on the way.   rate and reply
@ the Bell: TSX up at the end of the week on broad gains
The major deal between Canada’s two main telecom companies, Rogers and Shaw, made progress on Friday, helping the TSX close higher in a broad increase across sectors. Gains were capped on concerns... read article.

Neovasc Announces Second Quarter Financial Results

Generated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter of 2021. And COSIRA II protocol supplement was approved by the FDA, more than doubling the total number of patients and adding specific patient groups eligible and allowed for treatment in the trial. more

I hope everyone realizes, the FDA submission by LABS

of their Drug Master File is now the intellectual property of LABS.  Patent protection with rights to collect royalties.       rate and reply

This is the first time I've owned shares in a pharmaceutical

company.   LABS can say that "LEGALLY" because they have Drug Establishment License from Health but the like of Canopy, Tilray, and all the way down the line cannot make this more

NEPT on NASDAQ Soaring…also Watch SILO Wellness..SILO.c 📈

NEPT on NASDAQ Soaring…also Watch SILO Wellness..SILO.c DealFLOW wrote:Only 9 M shares ...recent consolidation....Co Ripe for SP Move...Very Volatile   Just the Image more

Growers in California and Europe now facing a once in a

1000 year drought.  West coast reservoirs are drying up with water restrictions being put in place.  Desalinization plants increase the cost of water adding overhead to those growers. more

RE:RE:Price creeping up

I have 40,000 shares that I bought at an average of ~$4.00.   rate and reply
The Market Herald’s Weekly Cannabis Report. August 12, 2022
Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023Source: Aleafia Health Inc.Aleafia Health (AH) reported its financial results for the three months ended June 30,... read article.

RE:RE:Price creeping up

So if I place a "market" buy order for 300,000 shares, where's the problem?  It's a small trade of less than $40K.   Money is like kinetic energy, it's not more

RE:Price creeping up

Will be lucky to hold .095 as too many shares available at 10. GLTA  rate and reply

RE:Price creeping up

There's no such thing as too many broski  rate and reply

RE:Price creeping up

I've got the same problem and buying more would just be greedy now.   rate and reply

Price creeping up

Can someone please buy some LABS shares at... .11 cents....get the ball rolling?   I already have too many shares.  rate and reply

Earnings this coming Monday before the bell.

Removing the debt servicing component from their balance sheet, anyone calculate how the elimination of debt will flow to the bottom line?  It's one full quarter with no debt on the more

Rightmolecules to fight cancer? Well that's not new at all.

Israel published papers and gave presentations about cannabinoid molecules in a variety of combinations that killed a varierty of different cancers years ago.  Matter of fact it was more

Cancer treatment using nanoparticle targeting and lipid

payload delivery.  We've been over this before, it's nothing new but what you put inside the lipid as the payload carrier is kind of new.   Good thing LABS has their more
Buzz on the Bullboards: Defying market expectations
Most market reviews are throwing around the dreaded R-word, “recession” like it’s going out of style. Once again, news headlines indicate that the markets may be steering towards one. It turns out... read article.

New Press Release - MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

BARRIE, ON, Aug. 11, 2022 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results for the three and article.

New CEO has lobbying experience.  rate and reply

AGRA.c Ready to skyRocket Cannabis Stocks Rebounding ✅🌿

AGRA.c Ready to skyRocket Cannabis Stocks Rebounding  2.2 Million Sq Grow Facilities.....One of Largest in North America.. Massive acerage....BIG LEVERAGE SHORTS soon Going more

Today's press release was obviously NOT covered by a Non

Disclosure Agreement.   To wit, the other "over 20 strong clinical trials" at various stages therefore are covered by Non Disclosure Agreements and point directly to working more

RE:LABS signs research agreement with USC

Does that partially explain Article 13 now?  There could be more as well.   rate and reply

LABS signs research agreement with USC  rate and reply